These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10402249)

  • 1. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
    Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
    Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
    Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
    J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
    Mensah-Osman EJ; Al-Katib AM; Mohammad RM
    Clin Cancer Res; 2003 Nov; 9(15):5794-7. PubMed ID: 14654565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
    Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
    Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
    al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
    Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
    Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
    Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
    Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
    Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
    Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
    Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
    Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
    Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.
    Nabha SM; Wall NR; Mohammad RM; Pettit GR; Al-Katib AM
    Anticancer Drugs; 2000 Jun; 11(5):385-92. PubMed ID: 10912955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
    Mohammad RM; Li Y; Mohamed AN; Pettit GR; Adsay V; Vaitkevicius VK; Al-Katib AM; Sarkar FH
    Pancreas; 1999 Nov; 19(4):353-61. PubMed ID: 10547195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
    Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
    Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
    Ditzel Santos D; Ho AW; Tournilhac O; Hatjiharissi E; Leleu X; Xu L; Tassone P; Neri P; Hunter ZR; Chemaly MA; Branagan AR; Manning RJ; Patterson CJ; Moreau AS; Ciccarelli B; Adamia S; Kriangkum J; Kutok JL; Tai YT; Zhang J; Pilarski LM; Anderson KC; Munshi N; Treon SP
    Exp Hematol; 2007 Sep; 35(9):1366-75. PubMed ID: 17761288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.